![Survival curves for inhibitor development ([A] any inhibitor; [B] high-titer inhibitor) according to the presence or absence of NNAs. See Figure 1 in the article by Cannavò et al that begins on page 1245.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/129/10/10.1182_blood-2017-01-760538/4/blood760538f1.jpeg?Expires=1731032190&Signature=a6I4yuVRTPBQaNex~aEsGqR1c~jsLkl9-suq~bVESzYZhJ~GNjq815WxCOibR4ekyHdXbIcZ46qKEUz4XkoX5C~0RtWu36WRhOTlgFnYBnumHD4-LCAJ5QPqQOGLw2EOoGKH~pEoK45Qa8FlzSkASu6flYvMyglnZQUy30Y-XVc-GN95TSKrGIJmZQTXTH5sr1wu6A67Y7-ZrTPGFAJNTsfsSOeVK~Mcj7C52ePYx-wCjXU2YrMoJBAtGk5T~D9Jb7k6J9iftzSg2UgGd9vDL1SBTvr0gfXgsP0BPwoZ6Z59qiLCEUsr-~mdNQAnuwFRroCNFOtFatf0POp28-f4Tg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Survival curves for inhibitor development ([A] any inhibitor; [B] high-titer inhibitor) according to the presence or absence of NNAs. See Figure 1 in the article by Cannavò et al that begins on page 1245.
Survival curves for inhibitor development ([A] any inhibitor; [B] high-titer inhibitor) according to the presence or absence of NNAs. See Figure 1 in the article by Cannavò et al that begins on page 1245.
